Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 20;9(5):e97605.
doi: 10.1371/journal.pone.0097605. eCollection 2014.

Computed tomography (CT) perfusion as an early predictive marker for treatment response to neoadjuvant chemotherapy in gastroesophageal junction cancer and gastric cancer--a prospective study

Affiliations

Computed tomography (CT) perfusion as an early predictive marker for treatment response to neoadjuvant chemotherapy in gastroesophageal junction cancer and gastric cancer--a prospective study

Martin Lundsgaard Hansen et al. PLoS One. .

Abstract

Objectives: To evaluate whether early reductions in CT perfusion parameters predict response to pre-operative chemotherapy prior to surgery for gastroesophageal junction (GEJ) and gastric cancer.

Materials and methods: Twenty-eight patients with adenocarcinoma of the gastro-esophageal junction (GEJ) and stomach were included. Patients received three series of chemotherapy before surgery, each consisting of a 3-week cycle of intravenous epirubicin, cisplatin or oxaliplatin, concomitant with capecitabine peroral. The patients were evaluated with a CT perfusion scan prior to, after the first series of, and after three series of chemotherapy. The CT perfusion scans were performed using a 320-detector row scanner. Tumour volume and perfusion parameters (arterial flow, blood volume and permeability) were computed on a dedicated workstation with a consensus between two radiologists. Response to chemotherapy was evaluated by two measures. Clinical response was defined as a tumour size reduction of more than 50%. Histological response was evaluated based on residual tumour cells in the surgical specimen using the standardized Mandard Score 1 to 5, in which values of 1 and 2 were classified as responders, and 3 to 5 were classified as nonresponders.

Results: A decrease in tumour permeability after one series of chemotherapy was positively correlated with clinical response after three series of chemotherapy. Significant changes in permeability and tumour volume were apparent after three series of chemotherapy in both clinical and histological responders. A cut-off value of more than 25% reduction in tumour permeability yielded a sensitivity of 69% and a specificity of 58% for predicting clinical response.

Conclusion: Early decrease in permeability is correlated with the likelihood of clinical response to pre-operative chemotherapy in GEJ and gastric cancer. As a single diagnostic test, CT Perfusion only has moderate sensitivity and specificity in response assessment of pre-operative chemotherapy making it insufficient for clinical decision purposes.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Illustration of histological response evaluation using Mandard score.
A) Tumour regression grade 2 (Mandard). Few, scattered residual cancer areas (arrows) separated by fibrosis (*). One tumour area is surrounding a vessel (V) and another tumour area is seen to the left. This patient was a histological responder. B) Tumour regression grade 4 (Mandard). Residual cancer areas (arrows) outgrowing fibrosis (*). This patient was a histological nonresponder.
Figure 2
Figure 2. CT perfusion images of a clinical responder.
Permeability ktrans parametric map in a clinical responder with a reduction in permeability between baseline and the first series of chemotherapy. A+B) Before chemotherapy (ktrans = 32.1 mL⋅min−1⋅100 g−1) C+D) After first series of chemotherapy (ktrans = 23.9 mL⋅min−1⋅100 g−1). Perfusion measures are averages from the entire tumor volume. The image illustrates perfusion measured in a reconstructed coronal plane which is possible with volume perfusion.
Figure 3
Figure 3. CT Perfusion images of a clinical nonresponder.
Permeability ktrans in a clinical nonresponder. An increase in ktrans is observed. E+F) Before chemotherapy (ktrans = 13.7 mL⋅min−1⋅100 g−1) and G+H) After first series of chemotherapy (ktrans = 21.0 mL⋅min−1⋅100 g−1). Perfusion measures are averages from the entire tumor volume.
Figure 4
Figure 4. Early changes in perfusion parameters and tumour volume in clinical responders.
Changes from baseline to first follow-up scan after first series of chemotherapy for the 27 cases available for early follow up evaluation. Each case is illustrated with a line between the baseline and the second scan. All values are in absolute numbers.
Figure 5
Figure 5. ROC analysis.
ROC curve with a cut-off value of 25% reduction in permeability between baseline and early follow up scan. Area under curve is 0.74 (Confidence interval 0.55–0.93).
Figure 6
Figure 6. Pre-operative scan and histological response based on Mandard Score.
Correlation between perfusion parameters pre-operatively and histological response. n = 27.

Similar articles

Cited by

References

    1. Li Z-P, Meng Q-F, Sun C-H, Xu D-S, Fan M, et al. (2005) Tumor angiogenesis and dynamic CT in colorectal carcinoma: radiologic-pathologic correlation. World J Gastroenterol 11: 1287–1291. - PMC - PubMed
    1. Hayano K, Okazumi S, Shuto K, Matsubara H, Shimada H, et al. (2007) Perfusion CT can predict the response to chemoradiation therapy and survival in esophageal squamous cell carcinoma: Initial clinical results. Oncology Reports 18: 901–908. - PubMed
    1. Koyasu S, Isoda H, Tsuji Y, Yamamoto H, Matsueda K, et al. (2012) Hepatic arterial perfusion increases in the early stage of severe acute pancreatitis patients: evaluation by perfusion computed tomography. Eur J Radiol 81: 43–46. - PubMed
    1. Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV (2012) Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 47: 11–17. - PubMed
    1. Fournier LS, Oudard S, Thiam R, Trinquart L, Banu E, et al. (2010) Metastatic Renal Carcinoma: Evaluation of Antiangiogenic Therapy with Dynamic Contrast-enhanced CT1. Radiology 256: 511–518. - PubMed

Publication types

Substances